CAFC Survival 24 Hours After 5-FU/KL Ablation
Treatment . | No. of Weekly Cycles . | CAFC Survival . | |||
---|---|---|---|---|---|
. | . | CAFC-7/HL . | (%) . | CAFC-28/HL . | (%) . |
Saline | 2 | 81,592 (61,131-108,901)ρ | 100 | 1,939 (1,427-2,634) | 100 |
5-FU | 1 | 2,258 (1,540-3,309) | 2.8 (1.9-4.1) | 1,164 (797-1,699) | 60 (41-88) |
5-FU | 2 | 2,827 (2,158-3,702) | 3.5 (2.6-4.5) | 952 (715-1,266) | 49 (37-65) |
5-FU + KL3-150 | 1 | 2,116 (1,433-3,126) | 2.6 (1.8-3.8) | 885 (557-1,408) | 45.6 (28.7-72.6) |
5-FU + KL3-151 | 2 | 127 (87-187) | 0.16 (0.11-0.23) | 263 (179-385) | 13.6 (9.2-19.9) |
5-FU + KL3-150 | 2 | 51 (39-66) | 0.06 (0.05-0.08) | 192 (148-250) | 9.9 (7.6-12.9) |
5-FU + KL + G-CSF3-152 | 2 | 23.4 (13.0-42.1) | 0.03 (0.02-0.05) | 319 (217-467) | 16.4 (11.2-24.1) |
Treatment . | No. of Weekly Cycles . | CAFC Survival . | |||
---|---|---|---|---|---|
. | . | CAFC-7/HL . | (%) . | CAFC-28/HL . | (%) . |
Saline | 2 | 81,592 (61,131-108,901)ρ | 100 | 1,939 (1,427-2,634) | 100 |
5-FU | 1 | 2,258 (1,540-3,309) | 2.8 (1.9-4.1) | 1,164 (797-1,699) | 60 (41-88) |
5-FU | 2 | 2,827 (2,158-3,702) | 3.5 (2.6-4.5) | 952 (715-1,266) | 49 (37-65) |
5-FU + KL3-150 | 1 | 2,116 (1,433-3,126) | 2.6 (1.8-3.8) | 885 (557-1,408) | 45.6 (28.7-72.6) |
5-FU + KL3-151 | 2 | 127 (87-187) | 0.16 (0.11-0.23) | 263 (179-385) | 13.6 (9.2-19.9) |
5-FU + KL3-150 | 2 | 51 (39-66) | 0.06 (0.05-0.08) | 192 (148-250) | 9.9 (7.6-12.9) |
5-FU + KL + G-CSF3-152 | 2 | 23.4 (13.0-42.1) | 0.03 (0.02-0.05) | 319 (217-467) | 16.4 (11.2-24.1) |